Ownership and insider activity for Enliven Therapeutics, Inc. (ELVN): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia.
Price
| Price | $50.18 |
| Market Cap | $3.6B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-17 | Hohl Benjamin | S-Sale | 4,630 | $270K |
| 2026-08-17 | Hohl Benjamin | S-Sale | 1,388 | $82K |
| 2026-08-17 | Collins Helen Louise | M-Exempt | 5,000 | $12K |
| 2026-08-17 | Collins Helen Louise | M-Exempt | 5,000 | $12K |
| 2026-08-17 | Collins Helen Louise | S-Sale | 3,900 | $228K |
| 2026-08-17 | Collins Helen Louise | S-Sale | 1,100 | $65K |
| 2026-08-04 | Derynck Mika K | M-Exempt | 20,491 | $460K |
| 2026-08-04 | Derynck Mika K | M-Exempt | 23,364 | $347K |
| 2026-08-04 | Derynck Mika K | M-Exempt | 27,567 | $697K |
| 2026-08-04 | Derynck Mika K | M-Exempt | 87,373 | $217K |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $9.7M | $7.4M | $4.9M | $47.7M | $110.0M | $75.5M | $100.1M | $124.1M | $98.9M |
| Short-term Investments | 0 | 0 | $24.0M | $40.5M | 0 | 0 | $153.0M | $189.3M | $363.7M |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $10.2M | $7.7M | $30.6M | $90.4M | $110.7M | $77.8M | $266.2M | $318.1M | $474.9M |
| Property, Plant & Equipment | 0 | 0 | $442000 | $349000 | $954000 | $1.5M | $1.1M | $458000 | $417000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $10.2M | $7.7M | $33.3M | $90.8M | $113.3M | $83.3M | $271.9M | $325.8M | $476.2M |
| Accounts Payable | $431000 | $908000 | $1.7M | $2.0M | $2.5M | $3.4M | $532000 | $1.3M | $2.2M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $826000 | $1.8M | $4.2M | $6.2M | $5.8M | $9.7M | $25.9M | $15.9M | $16.6M |
| Long-term Debt | $660000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $1.5M | $1.8M | $4.4M | $6.4M | $6.5M | $160.1M | $26.0M | $15.9M | $16.7M |
| Retained Earnings | -$20.0M | -$31.3M | -$54.8M | -$96.1M | -$45.2M | -$82.9M | -$154.4M | -$243.5M | -$347.2M |
| Total Equity | -$15.5M | -$26.3M | -$48.8M | $84.4M | $106.9M | -$76.8M | $245.9M | $309.8M | $459.6M |
| Total Debt | $660000 | 0 | 0 | 0 | $159000 | $323000 | $335000 | 0 | $399000 |
| Net Debt | -$9.0M | -$7.4M | -$28.9M | -$88.2M | -$109.9M | -$75.2M | -$252.8M | -$313.4M | -$462.2M |
| Working Capital | $9.4M | $5.9M | $26.4M | $84.2M | $104.9M | $68.0M | $240.3M | $302.2M | $458.3M |
Related companies: ATAI · DNTH · IMTX · INBX · NKTR · ORIC · PGEN
Explore sector: Healthcare · Biotechnology
More sections of ELVN: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks